Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | CKD-703 |
| Synonyms | |
| Therapy Description |
CKD-703 is an antibody-drug conjugate (ADC) targeting MET, which potentially inhibits tumor growth (Cancer Res (2024) 84 (7_Supplement): LB025). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| CKD-703 | CKD703|CKD 703 | MET Antibody 40 | CKD-703 is an antibody-drug conjugate (ADC) targeting MET, which potentially inhibits tumor growth (Cancer Res (2024) 84 (7_Supplement): LB025). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07439094 | Phase Ib/II | CKD-703 | A First-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell Lung Cancer | Recruiting | USA | 0 |